Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Fucosterol; EGCG; Scopoletin; Cholecalciferol; Celastrol (FESCC) augments the expression of FGF19 and FGF1, attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 26/September/2017, 9.15 pm
https://genomediscovery.org/wp-content/uploads/2017/09/Fucosterol-EGCG-Scopoletin-Cholecalciferol-Celastrol-induces-FGF1andFGF19-expression-and-attenuates-insulin-resistance.jpg1_.jpg
960
720
https://genomediscovery.org/wp-content/uploads/2017/09/Fucosterol-EGCG-Scopoletin-Cholecalciferol-Celastrol-induces-FGF1andFGF19-expression-and-attenuates-insulin-resistance.jpg1_.jpg
Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…
read more